Immunoprecise Antibodies Stock Fundamentals
| IPA Stock | USD 0.38 0.03 8.57% |
Immunoprecise Antibodies fundamentals help investors to digest information that contributes to Immunoprecise Antibodies' financial success or failures. It also enables traders to predict the movement of Immunoprecise Stock. The fundamental analysis module provides a way to measure Immunoprecise Antibodies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunoprecise Antibodies stock.
At present, Immunoprecise Antibodies' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 25.7 M, whereas Interest Expense is forecasted to decline to about 18.1 K. Immunoprecise | Select Account or Indicator |
Immunoprecise Antibodies Company Profit Margin Analysis
Immunoprecise Antibodies' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Immunoprecise Antibodies Profit Margin | (1.15) % |
Most of Immunoprecise Antibodies' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunoprecise Antibodies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Immunoprecise Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Immunoprecise Antibodies has a Profit Margin of -1.1522%. This is 89.72% lower than that of the Biotechnology sector and 95.0% lower than that of the Health Care industry. The profit margin for all United States stocks is 9.28% lower than that of the firm.
Immunoprecise Antibodies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immunoprecise Antibodies's current stock value. Our valuation model uses many indicators to compare Immunoprecise Antibodies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunoprecise Antibodies competition to find correlations between indicators driving Immunoprecise Antibodies's intrinsic value. More Info.Immunoprecise Antibodies is rated second overall in return on equity category among its peers. It also is rated second overall in return on asset category among its peers . At present, Immunoprecise Antibodies' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunoprecise Antibodies' earnings, one of the primary drivers of an investment's value.Immunoprecise Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunoprecise Antibodies' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunoprecise Antibodies could also be used in its relative valuation, which is a method of valuing Immunoprecise Antibodies by comparing valuation metrics of similar companies.Immunoprecise Antibodies is currently under evaluation in profit margin category among its peers.
Immunoprecise Antibodies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunoprecise Antibodies from analyzing Immunoprecise Antibodies' financial statements. These drivers represent accounts that assess Immunoprecise Antibodies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunoprecise Antibodies' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 49.9M | 52.8M | 197.4M | 140.7M | 86.7M | 45.2M | |
| Enterprise Value | 47.3M | 54.7M | 159.1M | 113.3M | 85.6M | 55.4M |
Immunoprecise Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (1.15) % | ||||
| Operating Margin | (0.86) % | ||||
| Current Valuation | 19.56 M | ||||
| Shares Outstanding | 28.83 M | ||||
| Shares Owned By Insiders | 12.05 % | ||||
| Shares Owned By Institutions | 6.50 % | ||||
| Number Of Shares Shorted | 666.14 K | ||||
| Price To Book | 0.46 X | ||||
| Price To Sales | 0.45 X | ||||
| Revenue | 24.52 M | ||||
| Gross Profit | 11.56 M | ||||
| EBITDA | (22.95 M) | ||||
| Net Income | (27.18 M) | ||||
| Cash And Equivalents | 19.24 M | ||||
| Cash Per Share | 0.77 X | ||||
| Total Debt | 13.68 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.06 X | ||||
| Book Value Per Share | 1.20 X | ||||
| Cash Flow From Operations | (4.25 M) | ||||
| Short Ratio | 0.73 X | ||||
| Earnings Per Share | (0.77) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 72 | ||||
| Beta | 0.27 | ||||
| Market Capitalization | 10.84 M | ||||
| Total Asset | 59.99 M | ||||
| Retained Earnings | (100.27 M) | ||||
| Working Capital | 3.36 M | ||||
| Net Asset | 59.99 M |
About Immunoprecise Antibodies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunoprecise Antibodies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunoprecise Antibodies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunoprecise Antibodies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.4 M | 1.4 M | |
| Total Revenue | 24.5 M | 25.7 M | |
| Cost Of Revenue | 12.5 M | 13.1 M | |
| Stock Based Compensation To Revenue | 0.06 | 0.06 | |
| Sales General And Administrative To Revenue | 0.64 | 0.04 | |
| Research And Ddevelopement To Revenue | 0.16 | 0.35 | |
| Capex To Revenue | 0.06 | 0.01 | |
| Revenue Per Share | 0.96 | 3.21 | |
| Ebit Per Revenue | (0.56) | (0.02) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:Check out Immunoprecise Antibodies Piotroski F Score and Immunoprecise Antibodies Altman Z Score analysis. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 0.921 | Quarterly Revenue Growth (0.07) | Return On Assets (0.13) | Return On Equity (0.64) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.